The PARP inhibitor olaparib enhances the sensitivity of Ewing sarcoma to trabectedin
Open accessThe DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
// José Luis Ordóñez 1,4,* , Ana Teresa Amaral 1,4,* , Angel M. Carcaboso 2 , David Herrero-Martín 3 , María del Carmen García-Macías 4 , Vicky Sevillano 4 , Diego Alonso 4 , Guillem Pascual-Pasto 2 , Laura San-Segundo 4 , Monica Vila-Ubach 2 , Telmo Rodrigues 4 , Susana Fraile 4 , Cristina Teodosio 4 , Agustín Mayo-Iscar 5 , Miguel Aracil 6 , Carlos María Galmarini 6 , Oscar M. Tirado 3 , Jaume Mora 2 and Enrique de Álava 1,4 1 Laboratory of Molecular Pathology, Instituto de Biomedicina de Sevilla (IBiS), Hospital Universitario Virgen del Rocio/CSIC/Universidad de Sevilla, Seville, Spain 2 Developmental Tumor Biology Laboratory, Preclinical Therapeutics and Drug Delivery Research Program, Hospital Sant Joan de Deu Barcelona, Spain 3 Sarcoma Research Group, Laboratori d’Oncología Molecular, Institut d’Investigació Biomèdica de Bellvitge (IDIBELL), L’Hospitalet de Llobregat, Barcelona, Spain 4 Centro de Investigación del Cáncer, Instituto de Biología Molecular y Celular del Cáncer/Consejo Superior de Investigaciones Científicas, Universidad de Salamanca, Salamanca, Spain 5 Statistics and Operations Research Department, University of Valladolid, Spain 6 Cell Biology and Pharmacogenomics Department, Pharmamar, Madrid, Spain * These authors have contributed equally to this work Correspondence to: José Luis Ordóñez García, email: // Enrique de Álava, email: // Keywords : Ewing sarcoma, PARP inhibitor, trabectedin, DNA damage, PDX models Received : March 13, 2015 Accepted : May 13, 2015 Published : May 27, 2015 Abstract Recent preclinical evidence has suggested that Ewing Sarcoma (ES) bearing EWSR1-ETS fusions could be particularly sensitive to PARP inhibitors (PARPinh) in combination with DNA damage repair (DDR) agents. Trabectedin is an antitumoral agent that modulates EWSR1-FLI1 transcriptional functions, causing DNA damage. Interestingly, PARP1 is also a transcriptional regulator of EWSR1-FLI1, and PARPinh disrupts the DDR machinery. Thus, given the impact and apparent specificity of both agents with regard to the DNA damage/DDR system and EWSR1-FLI1 activity in ES, we decided to explore the activity of combining PARPinh and Trabectedin in in vitro and in vivo experiments. The combination of Olaparib and Trabectedin was found to be highly synergistic, inhibiting cell proliferation, inducing apoptosis, and the accumulation of G2/M. The drug combination also enhanced γH2AX intranuclear accumulation as a result of DNA damage induction, DNA fragmentation and global DDR deregulation, while EWSR1-FLI1 target expression remained unaffected. The effect of the drug combination was corroborated in a mouse xenograft model of ES and, more importantly, in two ES patient-derived xenograft (PDX) models in which the tumors showed complete regression. In conclusion, the combination of the two agents leads to a biologically significant deregulation of the DDR machinery that elicits relevant antitumor activity in preclinical models and might represent a promising therapeutic tool that should be further explored for translation to the clinical setting.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Chou, T.-C., & Talalay, P. (1984) · Advances in Enzyme Regulation · doi:10.1016/0065-2571(84)90007-4 · Cited by 7,178 · cited 2×
“ES cell lines ( n = 10) were exposed to different combinations of both agents at a constant ratio of 1:20.000 (Trabectedin:Olaparib) for 72 hours and Combination Indices (CIs) were determined according to [15, 16].”
MethodInfluentialSpecific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase
Bryant, H. E., Schultz, N., Thomas, H. D., Parker, K. M., Flower, D., Lopez, E., Kyle, S., Meuth, M., Curtin, N. J., & Helleday, T. (2005) · Nature · doi:10.1038/nature03443 · Cited by 5,198
Systematic identification of genomic markers of drug sensitivity in cancer cells
Garnett, M. J., Edelman, E. J., Heidorn, S. J., Greenman, C. D., Dastur, A., Lau, K. W., Greninger, P., Thompson, I. R., Luo, X., Soares, J., et al. (2012) · Nature · doi:10.1038/nature11005 · Cited by 2,456 · cited 7×
“In ES in particular, sensitivity to PARPinh seems to be related to EWSR1-FLI1 transcriptional activity [6, 7].”
BackgroundResultInfluentialThe pediatric preclinical testing program: Description of models and early testing results
Houghton, P. J., Morton, C. L., Tucker, C., Payne, D., Favours, E., Cole, C., Gorlick, R., Kolb, E. A., Zhang, W., Lock, R., et al. (2007) · Pediatric Blood & Cancer · doi:10.1002/pbc.21078 · Cited by 480
Patient-derived Xenograft Models to Improve Targeted Therapy in Epithelial Ovarian Cancer Treatment
Scott, C. L., Becker, M. A., Haluska, P., & Samimi, G. (2013) · Frontiers in Oncology · doi:10.3389/fonc.2013.00295 · Cited by 100 · cited 1×
“PDX models have been shown to be biologically stable and to accurately reflect patient tumor biology and treatment response in other tumor types [26, 27].”
BackgroundAppraising iniparib, the PARP inhibitor that never was—what must we learn?
Mateo, J., Ong, M., Tan, D. S. P., Gonzalez, M. A., & de Bono, J. S. (2013) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2013.177 · Cited by 96
Cited by
Grünewald, T. G. P., Cidre-Aranaz, F., Surdez, D., Tomazou, E. M., de Álava, E., Kovar, H., Sorensen, P. H., Delattre, O., & Dirksen, U. (2018) · Nature Reviews Disease Primers · doi:10.1038/s41572-018-0003-x · Cited by 873
The ETS family of oncogenic transcription factors in solid tumours
Sizemore, G. M., Pitarresi, J. R., Balakrishnan, S., & Ostrowski, M. C. (2017) · Nature Reviews Cancer · doi:10.1038/nrc.2017.20 · Cited by 367
EWS/FLI confers tumor cell synthetic lethality to CDK12 inhibition in Ewing sarcoma
Iniguez, A. B., Stolte, B., Wang, E. J., Conway, A. S., Alexe, G., Dharia, N. V., Kwiatkowski, N., Zhang, T., Abraham, B. J., Mora, J., et al. (2018) · Cancer Cell · doi:10.1016/j.ccell.2017.12.009 · Cited by 173
“HSJDES-002 was established in athymic nude mice (Harlan, Barcelona, Spain) as previously described (Monterrubio et al., 2015; Ordonez et al., 2015).”
Self-citationUnderstanding Resistance Mechanisms and Expanding the Therapeutic Utility of PARP Inhibitors
Lim, J., & Tan, D. S. P. (2017) · Cancers · doi:10.3390/cancers9080109 · Cited by 52
“Combination strategies with other drugs such as trabectadin used in treatment of Ewing’s sarcoma have showed promising results in a preclinical setting, and clinical trials are currently underway to validate these findings in patients [50].”
BackgroundMurine Models of Bone Sarcomas
Jacques, C., Renema, N., Ory, B., Walkley, C. R., Grigoriadis, A. E., & Heymann, D. (2019) · Methods in Molecular Biology · doi:10.1007/978-1-4939-8997-3_18 · Cited by 14
Metadata
- Authors
- Ordóñez, J. L., Amaral, A. T., Carcaboso, A. M., Herrero-Martín, D., García-Macías, M. D. C., Sevillano, V., Alonso, D., Pascual-Pasto, G., San-Segundo, L., Vila-Ubach, M., Rodrigues, T., Fraile, S., Teodosio, C., Mayo-Iscar, A., Aracil, M., Galmarini, C. M., Tirado, O. M., Mora, J., & de Álava, E.
- Venue
- Oncotarget
- Publisher
- Impact Journals, LLC
- Published
- 2015-05-27
- Volume
- 6
- Issue
- 22
- Pages
- 18875-18890
- ISSN
- 1949-2553 (ISSN-L)
- OpenAlex
- W1566328614
- Cited by
- 95
- References
- 6
- FWCI
- 4.81
- Type
- journal article
- Language
- en
- Open access
- diamond
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.